Chinese biotech firm Gracell nets $100m from Wellington, OrbiMed, others

Photo by Dmitry Bayer on Unsplash

Chinese clinical-stage biopharmaceutical firm Gracell Biotechnologies Inc. has completed a $100 million Series C round co-led by the US investment company Wellington Management, New York-based OrbiMed Healthcare Fund Management, and VC firm 5Y Capital (formerly Morningside Venture Capital), the investee company said on Wednesday.

Vivo Capital, a new investor in Gracell, participated in the round, along with existing investors such as Singapore’s Temasek, Shanghai-based Lilly Asia Ventures (LAV), and US Kington Capital’s King Star Capital. 

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter